ERBB2 and ovarian cancer: Sixteen breast cancer (8 hormone‐receptor positive (HR+), 4 triple‐negative (TNBC), 4 epidermal growth receptor 2 (HER2) positive) and 12 ovarian cancer patients were enrolled.